Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 Monotherapy in KRAS p.G12C-Mutant Pancreatic Cancer and Other Solid Tumors
CTR20232444Phase 2Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glecirasib in pancreatic adenocarcinoma (PDAC), gastric cancer (GC), biliary cancer, small bowel cancer, ovarian cancer, sponsored by Jacobio Pharmaceuticals. Started Oct 2023; status: active.
02
Drugs
glecirasib
03
Conditions
pancreatic adenocarcinoma (PDAC)gastric cancer (GC)biliary cancersmall bowel cancerovarian cancer
Beyond the preview
Go deeper on CTR20232444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232444.